💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Technetium Medronate

CHEMBL2110576 Phase 4 معتمد Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
130.2 g/mol
LogP
2.5
Phase
4

Technetium medronate (99mTc-MDP, methylene diphosphonate) is the most widely used bone-scanning radiopharmaceutical, adsorbing to hydroxyapatite crystals in areas of increased osteoblastic activity and bone remodeling. It is used in whole-body bone scintigraphy for detection of bone metastases from cancers such as breast and bladder cancer, as well as for evaluation of osteomyelitis, fractures, and metabolic bone disease. The three-phase bone scan technique with this agent provides information on blood flow, blood pool, and delayed bone uptake.

الوزن الجزيئي

130,1800 g/mol

LogP

2,50

TPSA

37,30 Ų

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Breast Cancer Prostate Cancer Colorectal Cancer

آلية العمل

Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.

SMILES

CCCCCCC(=O)O

InChI

InChI=1S/C7H14O2/c1-2-3-4-5-6-7(8)9/h2-6H2,1H3,(H,8,9)

Molecular Formula

C7H14O2

HBD / HBA

1 / 2

الروابط القابلة للدوران

5

الذرات الثقيلة

9

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

Technetium medronate (99mTc-MDP, methylene diphosphonate) is the most widely used bone-scanning radiopharmaceutical, adsorbing to hydroxyapatite crystals in areas of increased osteoblastic activity and bone remodeling. It is used in whole-body bone scintigraphy for detection of bone metastases from cancers such as breast and bladder cancer, as well as for evaluation of osteomyelitis, fractures, and metabolic bone disease. The three-phase bone scan technique with this agent provides information on blood flow, blood pool, and delayed bone uptake.

Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.

Yes, Technetium Medronate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2110576. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 8094. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.